Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group
- 16 October 2019
- journal article
- review article
- Published by Elsevier BV in Journal of Infection
- Vol. 79 (6), 503-512
- https://doi.org/10.1016/j.jinf.2019.10.007
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 InfectionGastroenterology, 2015
- Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and DasabuvirAntimicrobial Agents and Chemotherapy, 2015
- Mixed HCV infection and reinfection in people who inject drugs—impact on therapyNature Reviews Gastroenterology & Hepatology, 2015
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)The Lancet Infectious Diseases, 2015
- Next‐generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatmentHepatology, 2014
- Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1Journal of General Virology, 2013
- Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South AfricaJournal of Medical Virology, 2012
- Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical PracticePLOS ONE, 2009
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoJournal of Virology, 2009
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998